GLAXF 6-K
GSK plc (GSK)
6-K
2026-07-09
For: 2026-07-09
View Original
Added on
July 09, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 9 July 2026, London UK
Roy Jakobs to join GSK Board as Non-Executive Director
GSK plc (LSE/NYSE: GSK) has today announced that Roy Jakobs will
join the Board of the Company as a Non-Executive Director from 13
July 2026.
Mr Jakobs is currently Chief Executive Officer of Royal Philips, a
global leader in health technology with sales of 17.8 billion EUR
in 2025 and 65,000 employees worldwide, headquartered in Amsterdam,
Netherlands.
Mr Jakobs has served as CEO of Royal Philips since 2022, and prior
to that held international roles of increasing seniority after
joining the company in 2010. Mr Jakobs has also held senior roles
at other global companies including Shell and Elsevier, and holds a
Master's in Business Administration (MBA).
Sir Jonathan Symonds, Chair of GSK said, "We
are delighted to welcome Roy to the Board. His experience as CEO of
a global health technology company, specialising in innovative
adjacent technologies to biopharmaceuticals including patient
monitoring, imaging, and intervention, will bring valuable
perspective to Luke and the Board. Roy's values and
approach to culture and purpose are highly aligned with our
own, and he is well-placed to support GSK as we focus on
accelerating growth and delivering better medicines for the
patients who need them and greater value for
shareholders."
Notes:
|
1.
The appointment of Mr Jakobs was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Board agreed a target skills matrix for the role and
was assisted and supported in candidate selection and evaluation by
an external search firm, which is a signatory of the Voluntary Code
of Conduct for Executive Search Firms. The Board satisfied itself
that Mr Jakobs had the experience and time available to carry out
the role.
|
|
2.
The Board has determined that Mr Jakobs is an independent
Non-Executive Director in accordance with the UK Corporate
Governance Code.
|
|
3.
Mr Jakobs will receive the standard annual fee for a Non-Executive
Director of £122,258. He will be required to build towards a
share ownership requirement of GSK shares in accordance with the
Company's shareholder approved Non-Executive Director Remuneration
policy - currently two times the standard annual
fee.
|
|
4.
Mr Jakobs does not have a service contract. He has a letter
of appointment which may be viewed by contacting the Company
Secretary at the Company's registered office.
|
|
5.
There are no further disclosures to be made in respect of Mr
Jakobs' appointment under Listing Rule 6.4.8R.
|
|
6.
As of 13 July 2026, the Board of GSK will comprise:
|
|
Sir
Jonathan Symonds CBE
|
Non-Executive
Chair
|
|
Luke
Miels
|
Chief
Executive Officer
|
|
Julie
Brown
|
Chief
Financial Officer
|
|
Charles
Bancroft
|
Senior
Independent Non-Executive Director
|
|
Elizabeth
McKee Anderson
|
Independent
Non-Executive Director
|
|
Dr Hal
Barron
|
Non-Executive
Director
|
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
|
Wendy
Becker CBE
|
Independent
Non-Executive Director
|
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
|
Roy
Jakobs
|
Independent
Non-Executive Director
|
|
Dr
Jeannie Lee
|
Independent
Non-Executive Director
|
|
Dr
Gavin Screaton
|
Independent
Non-Executive Director
|
|
Dr
Vishal Sikka
|
Independent
Non-Executive Director
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
09, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|